NASDAQ:ACHV Achieve Life Sciences Q2 2023 Earnings Report $1.99 -0.12 (-5.69%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.06 +0.08 (+3.77%) As of 04/17/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Achieve Life Sciences EPS ResultsActual EPS-$0.43Consensus EPS -$0.41Beat/MissMissed by -$0.02One Year Ago EPSN/AAchieve Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAchieve Life Sciences Announcement DetailsQuarterQ2 2023Date8/14/2023TimeN/AConference Call DateTuesday, August 15, 2023Conference Call Time8:30AM ETUpcoming EarningsAchieve Life Sciences' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Achieve Life Sciences Q2 2023 Earnings Call TranscriptProvided by QuartrAugust 15, 2023 ShareLink copied to clipboard.There are 9 speakers on the call. Operator00:00:00Greetings. Welcome to the Achieve Life Sciences Second Quarter 2023 Earnings Conference Call and Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. Operator00:00:22At this time, I would like to hand the call over to Nicole Jones, Investor Relations. Thank you. You may begin. Speaker 100:00:28Thank you, operator, and thank you to everyone for joining the call today. Today from Achieve, we have John Bincich, Chief Executive Officer Doctor. Cindy Jacobs, President and Chief Medical Officer and Jerry Wann, Principal Accounting Officer. Our Chief Management will be available for Q and A after the prepared remarks. I'd like to remind everyone that today's conference call contains forward looking statements based on current expectations. Speaker 100:00:55These statements are only predictions and actual results may vary materially from those projected. Please refer to Achieve documents available on our website and filed with the SEC concerning factors that could affect the company. I'll now turn the call over to John. Speaker 200:01:10Thank you, Nicole, and to everyone who has joined us this morning. The first half of twenty twenty three has seen the culmination of our ambitions to bring the first Smoking cessation product to market in nearly 20 years take a meaningful step forward. Several milestones were met in close proximity, all of which contributed substantial value to the cytisinicline program and to shareholders. Firstly, the ORCA-three Phase 3 trial results in May validated and closely replicated those of the ORCA-two trial and demonstrated significant efficacy with a benign side effect profile. Secondly, Just prior to the excellent ORCA-three results, Achieve announced positive results from the ORCA V1 Phase 2 clinical trial in 160 e cigarette users. Speaker 200:01:58Thirdly, Achieve renegotiated the terms of our convertible loan agreement, extending the maturity date. Fourthly, the Journal of American Medical Association or JAMA published our groundbreaking ORCA-two study. And finally, we raised additional capital providing cash runway well into 2024. Overall, significant progress was made on many fronts. We look forward to continuing the campaign to highlight the value of cytisinicline and the underlying public health importance of cytisinicline in the U. Speaker 200:02:30S. And globally. With both Phase 3 smoking cessation clinical trials completed in over 1500 subjects, the combined results Confirm the compelling efficacy and safety evidence of cytisinicline necessary to pursue FDA approval for smoking cessation. We are aiming to make an NDA submission in the first half of twenty twenty four and if approved cytisinicline could be the first new prescription treatment made available to the roughly 28,000,000 smokers in the U. S. Speaker 200:03:00In nearly 2 decades. In parallel with the regulatory activities, we continue to focus on commercial readiness with attention on CMC and supply chain as well as partnering discussions with interested parties around the globe who also believe in the immense potential of cytisinicline. Additionally, we can now expand our ambitions beyond the smoking cessation market and into the broader nicotine addiction market. As you are aware, vaping is expanding in popularity and serious concerns are continuing to emerge about both the short and long term safety of these products. Cytisinicline has the potential to be a 1st in class product for vaping cessation. Speaker 200:03:42Combined with the potential target market It's nearly 40,000,000 Americans who are currently either smoking or using e cigarettes. Looking at the data from both trials, specifically the 12 week treatment duration, the efficacy rates have exceeded what has been demonstrated historically by Chantix, bupropion or NRT. The primary endpoint that measured cessation rates during weeks 9 through 12 were over 30% with odds ratios Confirming that participants who received cytisinicline were 4 to 6 times more likely to quit compared to subjects on placebo. At the 24 week follow-up, the quit rates remained above 20% with odds ratios in the range of 5% to 6%. Although we did not include any head to head comparisons in our ORCA program, we can review previous trial results for reference. Speaker 200:04:35The most recent large scale randomized trial of approved smoking cessation treatments was the 8,000 Subject Eagles trial Conducted to better understand the neuropsychiatric effects of current agents. For the U. S. Population, quit rates at 24 weeks This is in line with the independent meta analyses published by the Cochrane Group, which observed odds ratios roughly between 23 for currently available agents. In addition, our ORCA program has validated a novel 6 week treatment arm, which is half the duration of existing medications. Speaker 200:05:17Importantly, even with this shorter course of therapy, we observed odds ratios that exceed those of existing treatments. We are very pleased with the efficacy observed to date with cytisinicline and its potential to make a meaningful impact for patients in this setting. Complimentary to the efficacy profile, the safety and tolerability we observed for cytisinicline in the ORCA program continues to shine and is described by the authors of the recent JAMA publication as excellent. As stated in the paper, only 2.9% of ORCA-two participants Discontinued cytisinicline due to an adverse event. Side effects have been reported as a major limitation to adoption and compliance of existing therapies. Speaker 200:06:02Ultimately, lack of compliance leads to unsuccessful quit attempts and smoking relapse. We believe the side effect profile of cytisinicline We'll compel many patients to make a quit attempt using the products, aid in adherence to the regimen and increase the likelihood of having a successful outcome. The safety should also be encouraging for prescribers who have long dealt with the management of treatment related side effects as well as concerns of the neuropsychiatric Finishing off on the clinical trial updates, we also announced in the Q2 the results of the ORCA V1 trial, Evaluating the safety and efficacy of cytisinicline for e cigarette cessation in 160 adults. We're extremely pleased to report a statistically significant benefit with a cessation rate of 31.8% for cytisinicline compared to 15.1% for placebo. Ultimately cytisinicline treated participants had a 2.6 times higher odds of quitting vaping compared to the placebo group. Speaker 200:07:07Again, cytisinicline was very well tolerated with no treatment related serious adverse events reported during the trial. Vaping continues to be a rapidly growing epidemic with over 11,000,000 Adults reporting nicotine vape use in 2021, a 22% increase over the prior year. In a survey published in JAMA, nearly 2,000 daily users of e cigarettes, 61% endorsed future plans to quit. Unfortunately, there are currently no treatments specifically FDA approved for e cigarette cessation, which is why we believe this is a unique opportunity to expand the utilization of cytisinicline and make a significant impact to overall public health. At this time, I'll hand It over to Jerry to review our financial highlights and results. Speaker 300:07:59Thanks, John. Beyond our clinical progress this quarter, We are also pleased to have successfully completed a capital raise with gross proceeds of $16,500,000 and further strengthened our financial position By refinancing our outstanding loan with Silicon Valley Bank, under the terms of the new loan agreement, the outstanding loan will now mature on December 22, 2024, providing a full 12 month extension from the previous maturity date. The other provisions regarding interest rate, conversion rates, Price and repayment remain materially unchanged. Turning to our statement of operations. The company incurred a net loss of $8,200,000 for the quarter ended June 30, 2023, as compared to a net loss of $10,500,000 for the same quarter in the prior year. Speaker 300:08:51Net loss for the 6 months ended June 30, 2023 decreased to $17,200,000 as compared to $18,000,000 for the same period of 2022. Operating expenses were lower for the quarter ended June 30, 2023 As both the ORCA-three Phase 3 trial and the ORCA V1 Phase 2 trial were successfully completed, we anticipate operating expenses in the second half of twenty twenty three to decline due to the completion of these trials, but partially offset By costs associated with the initiation Speaker 200:09:24of Speaker 300:09:25the additional NDA supporting PK study, ramp up of enrollment of the renal impairment trial, An increase in NDA preparation activities. As of June 30, 2023, The company's cash, cash equivalents and restricted cash were $25,100,000 as compared to $16,600,000 for the prior quarter. The increase in cash over the prior period was due to our registered direct offering, which closed in May 2023. We believe our current cash balance is sufficient to provide us runway into the second half of twenty twenty four. That concludes my update. Speaker 300:10:06I'd now like to turn the call back over to John. Speaker 200:10:09Thanks, Jerry. As a small company of only 22 full time employees, We are quite proud of our accomplishments and how far the cytisinicline program has advanced under our direction. That said, we fully recognize the challenges That lie ahead as we shift gears to prepare the NDA filing and look forward towards regulatory approval for cytisinicline in the U. S. The next focus for us in the regulatory process is holding a pre NDA meeting with the FDA, which is now scheduled to occur in the Q4. Speaker 200:10:41This will be an important meeting and affords us a final opportunity to solicit comments and clarification from the agency in advance of our NDA submission. We are continuing to guide to an NDA submission in the first half of twenty twenty four and hope to be in a position to refine our submission timing After we hold our pre NDA meeting. We continue to be excited about the market opportunity for cytisinicline, which we believe is uniquely positioned for success For a number of reasons. First, there is a large and underserved patient population of roughly 28,000,000 people who smoke cigarettes Approximately 11,000,000 people who use e cigarettes in the United States alone. There have been no new pharmacologic agents approved by the FDA in nearly 20 years and the treatment options that are currently available are not meeting the needs of patients or their healthcare providers. Speaker 200:11:362nd, there are significant political tailwinds to help advance smoking cessation treatments and strong advocacy for ensuring access to medications that have demonstrated robust clinical evidence of their efficacy and safety like cytisinicline. In addition, the Affordable Care Act ensures broad insurance coverage with minimal patient burden. And finally, There are currently no branded pharmaceutical cessation agents competing for prescriber or patient share of voice, Enabling cytisinicline the opportunity to pick up where Chantix left off. Before losing exclusivity, Chantix dominated the category with over $1,000,000,000 in global sales with 75% attributed to the U. S. Speaker 200:12:22Market And even priced at a modest discount and virtually no sales or marketing promotion, generic Chantix is generating over $300,000,000 in annual revenues and growing in the U. S. All of these elements combined with the challenging tolerability and high relapse rates Seen with existing therapies makes cytisinicline uniquely positioned for commercial success. It is truly exciting to work on a product that has such strong clinical evidence, is clearly differentiated and that has great potential to make a profound impact In closing, thank you all once again for your support and for joining us. We look forward to updating you on our progress. Speaker 200:13:05And at this time, I will now turn the call over to the operator for questions. Operator00:13:10Thank you. We will now be conducting a question and answer Our first questions come from the line of Thomas Flaten with Lake Street Capital. Please proceed with your questions. Speaker 400:13:46Hey, good morning. I appreciate you guys taking the questions. John, I was wondering if you could provide a little bit more color on the preclinical, non clinical work That's ongoing to support the NDA submission. Maybe a little bit more detail would be helpful. Speaker 200:14:01Yes. Thanks, Thomas. So, on the preclinical, nonclinical work, really not much happening on that front. Where we are focusing effort is on 3 remaining clinical studies. We've got a renal impairment trial that's ongoing, a QT Speaker 400:14:34Great. And then could you give us some sense of Sole Pharma's level of preparedness at this point for an FDA inspection? Are they ready now? Do you think they still need some time? Just some color there would be helpful. Speaker 200:14:47So with respect to Cell Pharma and the CMC This continues to be a high focus area for us. They will be the one of the manufacturers of record in our NDA. So we continue to spend a large amount of time and effort with So Pharma, ensuring that they will be Ready for a future FDA inspection. This is something that they have been used to with respect to EMA. But as we're all aware, FDA is another level above. Speaker 200:15:18So I think of all the areas, this will probably be one we continue to focus Our efforts as we proceed, but we do believe they'll be in a position ready for inspection as we crest into next year to get an NDA on file. Speaker 400:15:33And then just sticking with So Pharma, could you give us a sense of where you expect to be inventory wise as you Submit and then get approval. Speaker 200:15:44With respect to inventory, we continue to We've been building up a stockpile of cytisinicline in advance of a future launch. So this is something that will continue this year. We'd expect to have at the end of this year 3 to 4 years of launch quantity and we'll continue to grow that Into 2024 as well. Speaker 400:16:09Excellent. Appreciate taking the questions. Thank you. Operator00:16:14Thank you. Our next question comes from the line of Francois Brisebois with Oppenheimer. Please proceed with your questions. Speaker 500:16:22Hey, thanks for taking the questions. So in terms of the renal, the QT and the PK, is there anything there that's kind of the hardest hurdle or is this pretty Standard and nothing to really worry about in terms of those trials before submission. Speaker 200:16:38Yes. Thanks for the question, Frank. With respect to those three studies, there's really nothing that would derail the NDA. These are all things that would go into potentially Delabeling, renal in particular in terms of any dose reductions, things like that, but nothing that would change the overall product profile. So these are basically clinical studies that we need to check the box for FDA. Speaker 500:17:06Okay, great. And if you're thinking in terms of partnerships, is it these studies or maybe more the CMC side or anything you can share on color for Speaker 200:17:25So with respect to partnerships, I don't think any of these studies that you mentioned are really going to be Of high importance to any potential commercial partners. So we're not able to comment on any of the ongoing discussions that we're currently We think the data sets that we now have in hand from ORCA V1, ORCA 1, ORCA 2 and ORCA 3 in terms of the core clinical package are going to be the driving factors in terms of Assessment of the product profile and how that is going to be commercially viable. Speaker 500:18:08Great. And then if I could sneak in the last one, just on the e cigarette side, we've seen the data now. Can you just talk about I'm sorry if I missed this, the next steps here for that program? Speaker 200:18:20Yes. Thanks. Thanks, Frank. So with respect to the vaping indication, In the interim here, our focus will continue to be on NDA submission for smoking cessation. We're still working on pulling together the clinical study report for the ORCA V1 study. Speaker 200:18:38On the other side of that, we'll be in a position to start some of the work around Trial design, powering, budgeting of what that might look like. But again, the focus here in the near term is going to be on the NDA for smoking cessation. Speaker 500:18:55Thank you. Operator00:18:58Thank you. Our next questions come from the line of Michael Higgins with Ladenburg Thalmann. Please proceed with your question. Speaker 600:19:06Hey, guys. Good morning. This is Farhana on behalf of Michael. So two questions for us. So last week EndoSpaR Pharmaceuticals sued Zydus, saying it must be infringing its Nitrosamine impurity technique in a generic varenitine. Speaker 600:19:23And also last week, the FDA issued guidance that established a framework for assessing an acceptable level of nitrosamine in a drug protocol. So, are you confident that the manufacturing of Your drug is within the FDA's limit. And if so, is this something you can monetize with generic companies? And the second question we have is, do you plan to hire a marketing executive with experience in running a launch, Preferably one doing it without a pharma budget into a large non orphan market? And if so, when? Speaker 600:19:57Thanks. Speaker 200:20:00Yes, Zalana. Thanks for the questions there. So we have been tracking what's going on with the Endo launch. We I see the sales last year of north of $300,000,000 and the recent suit going across Desitis in terms of Potential IP violations with respect to another Chantix generic that's hitting the market. None of the IP that we see Sitting over there reads on to what we're doing. Speaker 200:20:29We do think we have an opportunity for new IP around Formulations on our side with respect to controlling for nitrosamines that we think could be blocking for others in this space. So that's something that we're actively working on in the background as we proceed and then obviously working In collaboration with FDA on final nitrosamine limits with respect to our drug product. So that's something that will continue as we proceed through So with respect to your second question on hiring another exec, This is not anything that we currently have planned at the moment. We've got a Head of Commercial that's leading the at the moment and our focus, I think, as you rightly indicated, is going to be on planning for a very nimble and efficient launch In parallel with continuing the partnering discussions, as we've indicated for quite some time, we've always believed that this asset is Likely best served in the hands of pharma or large biotech, a group that already has a primary care footprint in place. And so we want to make sure that we continue To tease out those discussions before making any investments in commercial. Speaker 600:21:52Okay, Great. Thank you. I'll jump back in the queue. Operator00:21:58Thank you. Our next question comes from the line of James Molloy with Alliance Resource Partners. Please proceed with your questions. Speaker 700:22:06Hello. This is Laura Sorel calling in for Jim Molloy. Thank you for taking the So with the higher odds of ratio of the higher odds of quitting seen in the 12 week treatment arm versus the 6 week treatment arm in the Speaker 200:22:29Thanks for the question, Laura. So with respect to the presentation commercially, we think it would it likely will read up to 12 weeks of treatment. So from a physician perspective, they would prescribe 12 weeks of cytisinicline. Patient would fill 6 weeks. If they need a little bit longer to quit, then they would go back and refill for that incremental 6 weeks to do the full 12 week course of medication. Speaker 200:22:57And I think the beauty of what we've built here is that we've got validated data with even half the duration Of the existing products on the market, which we think is a novel presentation in the market. Speaker 700:23:13Got it. Thanks for the clarity. And then also with the Phase 2 ORCA V1 trial now complete, what's the status on a potential trial of Speaker 200:23:26So with respect to a pediatric indication for vaping, This is something that's likely going to be well down the road. Our focus in the interim is going to be on adult e cigarette users, Similar to what we've done on the smoking cessation side, obviously, the youth epidemic in vaping is Monumentally big and that's gotten a lot of the PR here over the last 5 years. So we do think it is something that needs to be addressed. But I think 1st and foremost For us is getting that indication opened up on the marketplace and allowing it to be prescribed as such Before diving into what we believe will be a difficult population to treat. Speaker 700:24:12Got it. Thanks for the questions and congrats on the progress this quarter. Speaker 800:24:17Thanks, Laura. Operator00:24:19Thank you. Our next questions come from the line of John Vandermosten with Zacks Research. Please proceed with your questions. Speaker 800:24:26Thank you and good morning, John. How are you doing? Speaker 200:24:29Great. Speaker 800:24:32So in our research, we have identified a number of potential suitors for Achieve, including Pfizer, GSK, Perrigo, Doctor. Reyes and a bunch of others. Do you think that it might make sense to have one deal or potentially multiple deals, because there's different regions just may have different opportunities that I'm thinking New Zealand, Australia, example, there's a lot of focus on cytisinicline and gene vaping and a whole bunch of other things that make that a Your attractive region, is there anything that might cause you to split it up or does it make more sense to have one partner that fully commercializes the product? Speaker 200:25:10Yes. Thanks for the question, John. With respect to our ideal partner, it would be a single global partner that has capabilities In all the various territories around the world that we're interested in. I think with that being said, given that the U. S. Speaker 200:25:27Has been such a substantial portion Of revenues globally, when looking at Chantix as a proxy, strong U. S. Capabilities are going to be critical for this launch. With that being said, we've seen a tremendous amount of interest out of Asia over the years. We have seen multiple term sheets For deals in those regions, we specifically not move forward with them, so we can play out the potential for a larger single transaction. Speaker 200:25:57But I think there are opportunities. I think like you said, across the globe, there is a need kind of everywhere you look given that there's over a1000000000 smokers around the globe. So I think that's kind of the ordering we're thinking about single global partner first before we start thinking about multiple deals. Speaker 800:26:17Sounds good. Yes, and China seems particularly attractive as well because I think they're making a lot of efforts to cut smoking and it's a pretty high incidence rate over there as well. And then back to the potential suitors, do you think pharma's appetite is more to go before approval comes or to wait until it's a certain thing. I think there's been a lot less type of risk recently. And I'm just wondering kind of what your sense is On how Big Pharma is thinking about willing to transact based on regulatory hurdles? Speaker 200:26:52Yes. So in terms of willingness from pharma, I mean, I think the good news is we've seen an uptick in M and A activity as well as That are coming over the next 2 to 3 years. So there is a need to replace some of that with new revenues. So we think all that kind of shapes up well as we kind of make the push to find a commercial partner. Speaker 800:27:26Okay, great. And have you seen any studies out there put in place? And I've seen a few out there. They seem rather small, maybe funded by governments, but You know, measuring cytisinicline and perhaps a head to head study or something that we're going to claim. Speaker 200:27:42Yes. With respect to other ongoing studies or recent results, not aware of any. We've got the Australian study as well as the New Zealand study That we're head to head against Chantix, but outside of that, not aware of any sort of large scale trials like that That are ongoing. Speaker 800:28:04Great. Thanks, John. Operator00:28:08Thank you. We have reached the end of our question and answer session. I would now like to turn the floor back over to John Bencic for closing comments. Speaker 200:28:16Thanks again everyone for joining us today. The second quarter was a very pivotal one for us with Critical data points both in the vaping side of the equation as well as for smoking cessation and getting through our second and final Phase 3 trial. So really excited about the progress we've made and look forward to providing additional updates as we move forward to a future NDA submission. Thanks again for joining us today. Operator00:28:43Thank you. This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallAchieve Life Sciences Q2 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Achieve Life Sciences Earnings HeadlinesJonesTrading Keeps Their Buy Rating on Achieve Life Sciences (ACHV)April 2, 2025 | markets.businessinsider.comD-Wave Claims to Achieve ‘Quantum Supremacy’ — Some Researchers DisagreeMarch 30, 2025 | techrepublic.comThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.April 20, 2025 | Investors Alley (Ad)Achieve Life Sciences, Inc. (ACHV): A Bull Case TheoryMarch 20, 2025 | insidermonkey.comACHV: 2Q:25 NDA SubmissionMarch 12, 2025 | msn.comAchieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | insidermonkey.comSee More Achieve Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Achieve Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achieve Life Sciences and other key companies, straight to your email. Email Address About Achieve Life SciencesAchieve Life Sciences (NASDAQ:ACHV), a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.View Achieve Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 9 speakers on the call. Operator00:00:00Greetings. Welcome to the Achieve Life Sciences Second Quarter 2023 Earnings Conference Call and Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. Operator00:00:22At this time, I would like to hand the call over to Nicole Jones, Investor Relations. Thank you. You may begin. Speaker 100:00:28Thank you, operator, and thank you to everyone for joining the call today. Today from Achieve, we have John Bincich, Chief Executive Officer Doctor. Cindy Jacobs, President and Chief Medical Officer and Jerry Wann, Principal Accounting Officer. Our Chief Management will be available for Q and A after the prepared remarks. I'd like to remind everyone that today's conference call contains forward looking statements based on current expectations. Speaker 100:00:55These statements are only predictions and actual results may vary materially from those projected. Please refer to Achieve documents available on our website and filed with the SEC concerning factors that could affect the company. I'll now turn the call over to John. Speaker 200:01:10Thank you, Nicole, and to everyone who has joined us this morning. The first half of twenty twenty three has seen the culmination of our ambitions to bring the first Smoking cessation product to market in nearly 20 years take a meaningful step forward. Several milestones were met in close proximity, all of which contributed substantial value to the cytisinicline program and to shareholders. Firstly, the ORCA-three Phase 3 trial results in May validated and closely replicated those of the ORCA-two trial and demonstrated significant efficacy with a benign side effect profile. Secondly, Just prior to the excellent ORCA-three results, Achieve announced positive results from the ORCA V1 Phase 2 clinical trial in 160 e cigarette users. Speaker 200:01:58Thirdly, Achieve renegotiated the terms of our convertible loan agreement, extending the maturity date. Fourthly, the Journal of American Medical Association or JAMA published our groundbreaking ORCA-two study. And finally, we raised additional capital providing cash runway well into 2024. Overall, significant progress was made on many fronts. We look forward to continuing the campaign to highlight the value of cytisinicline and the underlying public health importance of cytisinicline in the U. Speaker 200:02:30S. And globally. With both Phase 3 smoking cessation clinical trials completed in over 1500 subjects, the combined results Confirm the compelling efficacy and safety evidence of cytisinicline necessary to pursue FDA approval for smoking cessation. We are aiming to make an NDA submission in the first half of twenty twenty four and if approved cytisinicline could be the first new prescription treatment made available to the roughly 28,000,000 smokers in the U. S. Speaker 200:03:00In nearly 2 decades. In parallel with the regulatory activities, we continue to focus on commercial readiness with attention on CMC and supply chain as well as partnering discussions with interested parties around the globe who also believe in the immense potential of cytisinicline. Additionally, we can now expand our ambitions beyond the smoking cessation market and into the broader nicotine addiction market. As you are aware, vaping is expanding in popularity and serious concerns are continuing to emerge about both the short and long term safety of these products. Cytisinicline has the potential to be a 1st in class product for vaping cessation. Speaker 200:03:42Combined with the potential target market It's nearly 40,000,000 Americans who are currently either smoking or using e cigarettes. Looking at the data from both trials, specifically the 12 week treatment duration, the efficacy rates have exceeded what has been demonstrated historically by Chantix, bupropion or NRT. The primary endpoint that measured cessation rates during weeks 9 through 12 were over 30% with odds ratios Confirming that participants who received cytisinicline were 4 to 6 times more likely to quit compared to subjects on placebo. At the 24 week follow-up, the quit rates remained above 20% with odds ratios in the range of 5% to 6%. Although we did not include any head to head comparisons in our ORCA program, we can review previous trial results for reference. Speaker 200:04:35The most recent large scale randomized trial of approved smoking cessation treatments was the 8,000 Subject Eagles trial Conducted to better understand the neuropsychiatric effects of current agents. For the U. S. Population, quit rates at 24 weeks This is in line with the independent meta analyses published by the Cochrane Group, which observed odds ratios roughly between 23 for currently available agents. In addition, our ORCA program has validated a novel 6 week treatment arm, which is half the duration of existing medications. Speaker 200:05:17Importantly, even with this shorter course of therapy, we observed odds ratios that exceed those of existing treatments. We are very pleased with the efficacy observed to date with cytisinicline and its potential to make a meaningful impact for patients in this setting. Complimentary to the efficacy profile, the safety and tolerability we observed for cytisinicline in the ORCA program continues to shine and is described by the authors of the recent JAMA publication as excellent. As stated in the paper, only 2.9% of ORCA-two participants Discontinued cytisinicline due to an adverse event. Side effects have been reported as a major limitation to adoption and compliance of existing therapies. Speaker 200:06:02Ultimately, lack of compliance leads to unsuccessful quit attempts and smoking relapse. We believe the side effect profile of cytisinicline We'll compel many patients to make a quit attempt using the products, aid in adherence to the regimen and increase the likelihood of having a successful outcome. The safety should also be encouraging for prescribers who have long dealt with the management of treatment related side effects as well as concerns of the neuropsychiatric Finishing off on the clinical trial updates, we also announced in the Q2 the results of the ORCA V1 trial, Evaluating the safety and efficacy of cytisinicline for e cigarette cessation in 160 adults. We're extremely pleased to report a statistically significant benefit with a cessation rate of 31.8% for cytisinicline compared to 15.1% for placebo. Ultimately cytisinicline treated participants had a 2.6 times higher odds of quitting vaping compared to the placebo group. Speaker 200:07:07Again, cytisinicline was very well tolerated with no treatment related serious adverse events reported during the trial. Vaping continues to be a rapidly growing epidemic with over 11,000,000 Adults reporting nicotine vape use in 2021, a 22% increase over the prior year. In a survey published in JAMA, nearly 2,000 daily users of e cigarettes, 61% endorsed future plans to quit. Unfortunately, there are currently no treatments specifically FDA approved for e cigarette cessation, which is why we believe this is a unique opportunity to expand the utilization of cytisinicline and make a significant impact to overall public health. At this time, I'll hand It over to Jerry to review our financial highlights and results. Speaker 300:07:59Thanks, John. Beyond our clinical progress this quarter, We are also pleased to have successfully completed a capital raise with gross proceeds of $16,500,000 and further strengthened our financial position By refinancing our outstanding loan with Silicon Valley Bank, under the terms of the new loan agreement, the outstanding loan will now mature on December 22, 2024, providing a full 12 month extension from the previous maturity date. The other provisions regarding interest rate, conversion rates, Price and repayment remain materially unchanged. Turning to our statement of operations. The company incurred a net loss of $8,200,000 for the quarter ended June 30, 2023, as compared to a net loss of $10,500,000 for the same quarter in the prior year. Speaker 300:08:51Net loss for the 6 months ended June 30, 2023 decreased to $17,200,000 as compared to $18,000,000 for the same period of 2022. Operating expenses were lower for the quarter ended June 30, 2023 As both the ORCA-three Phase 3 trial and the ORCA V1 Phase 2 trial were successfully completed, we anticipate operating expenses in the second half of twenty twenty three to decline due to the completion of these trials, but partially offset By costs associated with the initiation Speaker 200:09:24of Speaker 300:09:25the additional NDA supporting PK study, ramp up of enrollment of the renal impairment trial, An increase in NDA preparation activities. As of June 30, 2023, The company's cash, cash equivalents and restricted cash were $25,100,000 as compared to $16,600,000 for the prior quarter. The increase in cash over the prior period was due to our registered direct offering, which closed in May 2023. We believe our current cash balance is sufficient to provide us runway into the second half of twenty twenty four. That concludes my update. Speaker 300:10:06I'd now like to turn the call back over to John. Speaker 200:10:09Thanks, Jerry. As a small company of only 22 full time employees, We are quite proud of our accomplishments and how far the cytisinicline program has advanced under our direction. That said, we fully recognize the challenges That lie ahead as we shift gears to prepare the NDA filing and look forward towards regulatory approval for cytisinicline in the U. S. The next focus for us in the regulatory process is holding a pre NDA meeting with the FDA, which is now scheduled to occur in the Q4. Speaker 200:10:41This will be an important meeting and affords us a final opportunity to solicit comments and clarification from the agency in advance of our NDA submission. We are continuing to guide to an NDA submission in the first half of twenty twenty four and hope to be in a position to refine our submission timing After we hold our pre NDA meeting. We continue to be excited about the market opportunity for cytisinicline, which we believe is uniquely positioned for success For a number of reasons. First, there is a large and underserved patient population of roughly 28,000,000 people who smoke cigarettes Approximately 11,000,000 people who use e cigarettes in the United States alone. There have been no new pharmacologic agents approved by the FDA in nearly 20 years and the treatment options that are currently available are not meeting the needs of patients or their healthcare providers. Speaker 200:11:362nd, there are significant political tailwinds to help advance smoking cessation treatments and strong advocacy for ensuring access to medications that have demonstrated robust clinical evidence of their efficacy and safety like cytisinicline. In addition, the Affordable Care Act ensures broad insurance coverage with minimal patient burden. And finally, There are currently no branded pharmaceutical cessation agents competing for prescriber or patient share of voice, Enabling cytisinicline the opportunity to pick up where Chantix left off. Before losing exclusivity, Chantix dominated the category with over $1,000,000,000 in global sales with 75% attributed to the U. S. Speaker 200:12:22Market And even priced at a modest discount and virtually no sales or marketing promotion, generic Chantix is generating over $300,000,000 in annual revenues and growing in the U. S. All of these elements combined with the challenging tolerability and high relapse rates Seen with existing therapies makes cytisinicline uniquely positioned for commercial success. It is truly exciting to work on a product that has such strong clinical evidence, is clearly differentiated and that has great potential to make a profound impact In closing, thank you all once again for your support and for joining us. We look forward to updating you on our progress. Speaker 200:13:05And at this time, I will now turn the call over to the operator for questions. Operator00:13:10Thank you. We will now be conducting a question and answer Our first questions come from the line of Thomas Flaten with Lake Street Capital. Please proceed with your questions. Speaker 400:13:46Hey, good morning. I appreciate you guys taking the questions. John, I was wondering if you could provide a little bit more color on the preclinical, non clinical work That's ongoing to support the NDA submission. Maybe a little bit more detail would be helpful. Speaker 200:14:01Yes. Thanks, Thomas. So, on the preclinical, nonclinical work, really not much happening on that front. Where we are focusing effort is on 3 remaining clinical studies. We've got a renal impairment trial that's ongoing, a QT Speaker 400:14:34Great. And then could you give us some sense of Sole Pharma's level of preparedness at this point for an FDA inspection? Are they ready now? Do you think they still need some time? Just some color there would be helpful. Speaker 200:14:47So with respect to Cell Pharma and the CMC This continues to be a high focus area for us. They will be the one of the manufacturers of record in our NDA. So we continue to spend a large amount of time and effort with So Pharma, ensuring that they will be Ready for a future FDA inspection. This is something that they have been used to with respect to EMA. But as we're all aware, FDA is another level above. Speaker 200:15:18So I think of all the areas, this will probably be one we continue to focus Our efforts as we proceed, but we do believe they'll be in a position ready for inspection as we crest into next year to get an NDA on file. Speaker 400:15:33And then just sticking with So Pharma, could you give us a sense of where you expect to be inventory wise as you Submit and then get approval. Speaker 200:15:44With respect to inventory, we continue to We've been building up a stockpile of cytisinicline in advance of a future launch. So this is something that will continue this year. We'd expect to have at the end of this year 3 to 4 years of launch quantity and we'll continue to grow that Into 2024 as well. Speaker 400:16:09Excellent. Appreciate taking the questions. Thank you. Operator00:16:14Thank you. Our next question comes from the line of Francois Brisebois with Oppenheimer. Please proceed with your questions. Speaker 500:16:22Hey, thanks for taking the questions. So in terms of the renal, the QT and the PK, is there anything there that's kind of the hardest hurdle or is this pretty Standard and nothing to really worry about in terms of those trials before submission. Speaker 200:16:38Yes. Thanks for the question, Frank. With respect to those three studies, there's really nothing that would derail the NDA. These are all things that would go into potentially Delabeling, renal in particular in terms of any dose reductions, things like that, but nothing that would change the overall product profile. So these are basically clinical studies that we need to check the box for FDA. Speaker 500:17:06Okay, great. And if you're thinking in terms of partnerships, is it these studies or maybe more the CMC side or anything you can share on color for Speaker 200:17:25So with respect to partnerships, I don't think any of these studies that you mentioned are really going to be Of high importance to any potential commercial partners. So we're not able to comment on any of the ongoing discussions that we're currently We think the data sets that we now have in hand from ORCA V1, ORCA 1, ORCA 2 and ORCA 3 in terms of the core clinical package are going to be the driving factors in terms of Assessment of the product profile and how that is going to be commercially viable. Speaker 500:18:08Great. And then if I could sneak in the last one, just on the e cigarette side, we've seen the data now. Can you just talk about I'm sorry if I missed this, the next steps here for that program? Speaker 200:18:20Yes. Thanks. Thanks, Frank. So with respect to the vaping indication, In the interim here, our focus will continue to be on NDA submission for smoking cessation. We're still working on pulling together the clinical study report for the ORCA V1 study. Speaker 200:18:38On the other side of that, we'll be in a position to start some of the work around Trial design, powering, budgeting of what that might look like. But again, the focus here in the near term is going to be on the NDA for smoking cessation. Speaker 500:18:55Thank you. Operator00:18:58Thank you. Our next questions come from the line of Michael Higgins with Ladenburg Thalmann. Please proceed with your question. Speaker 600:19:06Hey, guys. Good morning. This is Farhana on behalf of Michael. So two questions for us. So last week EndoSpaR Pharmaceuticals sued Zydus, saying it must be infringing its Nitrosamine impurity technique in a generic varenitine. Speaker 600:19:23And also last week, the FDA issued guidance that established a framework for assessing an acceptable level of nitrosamine in a drug protocol. So, are you confident that the manufacturing of Your drug is within the FDA's limit. And if so, is this something you can monetize with generic companies? And the second question we have is, do you plan to hire a marketing executive with experience in running a launch, Preferably one doing it without a pharma budget into a large non orphan market? And if so, when? Speaker 600:19:57Thanks. Speaker 200:20:00Yes, Zalana. Thanks for the questions there. So we have been tracking what's going on with the Endo launch. We I see the sales last year of north of $300,000,000 and the recent suit going across Desitis in terms of Potential IP violations with respect to another Chantix generic that's hitting the market. None of the IP that we see Sitting over there reads on to what we're doing. Speaker 200:20:29We do think we have an opportunity for new IP around Formulations on our side with respect to controlling for nitrosamines that we think could be blocking for others in this space. So that's something that we're actively working on in the background as we proceed and then obviously working In collaboration with FDA on final nitrosamine limits with respect to our drug product. So that's something that will continue as we proceed through So with respect to your second question on hiring another exec, This is not anything that we currently have planned at the moment. We've got a Head of Commercial that's leading the at the moment and our focus, I think, as you rightly indicated, is going to be on planning for a very nimble and efficient launch In parallel with continuing the partnering discussions, as we've indicated for quite some time, we've always believed that this asset is Likely best served in the hands of pharma or large biotech, a group that already has a primary care footprint in place. And so we want to make sure that we continue To tease out those discussions before making any investments in commercial. Speaker 600:21:52Okay, Great. Thank you. I'll jump back in the queue. Operator00:21:58Thank you. Our next question comes from the line of James Molloy with Alliance Resource Partners. Please proceed with your questions. Speaker 700:22:06Hello. This is Laura Sorel calling in for Jim Molloy. Thank you for taking the So with the higher odds of ratio of the higher odds of quitting seen in the 12 week treatment arm versus the 6 week treatment arm in the Speaker 200:22:29Thanks for the question, Laura. So with respect to the presentation commercially, we think it would it likely will read up to 12 weeks of treatment. So from a physician perspective, they would prescribe 12 weeks of cytisinicline. Patient would fill 6 weeks. If they need a little bit longer to quit, then they would go back and refill for that incremental 6 weeks to do the full 12 week course of medication. Speaker 200:22:57And I think the beauty of what we've built here is that we've got validated data with even half the duration Of the existing products on the market, which we think is a novel presentation in the market. Speaker 700:23:13Got it. Thanks for the clarity. And then also with the Phase 2 ORCA V1 trial now complete, what's the status on a potential trial of Speaker 200:23:26So with respect to a pediatric indication for vaping, This is something that's likely going to be well down the road. Our focus in the interim is going to be on adult e cigarette users, Similar to what we've done on the smoking cessation side, obviously, the youth epidemic in vaping is Monumentally big and that's gotten a lot of the PR here over the last 5 years. So we do think it is something that needs to be addressed. But I think 1st and foremost For us is getting that indication opened up on the marketplace and allowing it to be prescribed as such Before diving into what we believe will be a difficult population to treat. Speaker 700:24:12Got it. Thanks for the questions and congrats on the progress this quarter. Speaker 800:24:17Thanks, Laura. Operator00:24:19Thank you. Our next questions come from the line of John Vandermosten with Zacks Research. Please proceed with your questions. Speaker 800:24:26Thank you and good morning, John. How are you doing? Speaker 200:24:29Great. Speaker 800:24:32So in our research, we have identified a number of potential suitors for Achieve, including Pfizer, GSK, Perrigo, Doctor. Reyes and a bunch of others. Do you think that it might make sense to have one deal or potentially multiple deals, because there's different regions just may have different opportunities that I'm thinking New Zealand, Australia, example, there's a lot of focus on cytisinicline and gene vaping and a whole bunch of other things that make that a Your attractive region, is there anything that might cause you to split it up or does it make more sense to have one partner that fully commercializes the product? Speaker 200:25:10Yes. Thanks for the question, John. With respect to our ideal partner, it would be a single global partner that has capabilities In all the various territories around the world that we're interested in. I think with that being said, given that the U. S. Speaker 200:25:27Has been such a substantial portion Of revenues globally, when looking at Chantix as a proxy, strong U. S. Capabilities are going to be critical for this launch. With that being said, we've seen a tremendous amount of interest out of Asia over the years. We have seen multiple term sheets For deals in those regions, we specifically not move forward with them, so we can play out the potential for a larger single transaction. Speaker 200:25:57But I think there are opportunities. I think like you said, across the globe, there is a need kind of everywhere you look given that there's over a1000000000 smokers around the globe. So I think that's kind of the ordering we're thinking about single global partner first before we start thinking about multiple deals. Speaker 800:26:17Sounds good. Yes, and China seems particularly attractive as well because I think they're making a lot of efforts to cut smoking and it's a pretty high incidence rate over there as well. And then back to the potential suitors, do you think pharma's appetite is more to go before approval comes or to wait until it's a certain thing. I think there's been a lot less type of risk recently. And I'm just wondering kind of what your sense is On how Big Pharma is thinking about willing to transact based on regulatory hurdles? Speaker 200:26:52Yes. So in terms of willingness from pharma, I mean, I think the good news is we've seen an uptick in M and A activity as well as That are coming over the next 2 to 3 years. So there is a need to replace some of that with new revenues. So we think all that kind of shapes up well as we kind of make the push to find a commercial partner. Speaker 800:27:26Okay, great. And have you seen any studies out there put in place? And I've seen a few out there. They seem rather small, maybe funded by governments, but You know, measuring cytisinicline and perhaps a head to head study or something that we're going to claim. Speaker 200:27:42Yes. With respect to other ongoing studies or recent results, not aware of any. We've got the Australian study as well as the New Zealand study That we're head to head against Chantix, but outside of that, not aware of any sort of large scale trials like that That are ongoing. Speaker 800:28:04Great. Thanks, John. Operator00:28:08Thank you. We have reached the end of our question and answer session. I would now like to turn the floor back over to John Bencic for closing comments. Speaker 200:28:16Thanks again everyone for joining us today. The second quarter was a very pivotal one for us with Critical data points both in the vaping side of the equation as well as for smoking cessation and getting through our second and final Phase 3 trial. So really excited about the progress we've made and look forward to providing additional updates as we move forward to a future NDA submission. Thanks again for joining us today. Operator00:28:43Thank you. This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.Read morePowered by